Literature DB >> 28536920

Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study.

Elodie Rivière1, Fleur Cohen Aubart2,3,4, Thierry Maisonobe5, François Maurier6, Christophe Richez7, Bruno Gombert8, Marie Gousseff9, Daniel Adoue10, Alexis Mathian1, Miguel Hié1, Julien Haroche1,11, Zahir Amoura1,11.   

Abstract

Multiple mononeuropathy (MM) occurs rarely during systemic lupus erythematosus (SLE) but may lead to major disability. The aim of this study was to investigate the clinic-pathological presentations of MM during SLE, as well as long-term outcomes. We conducted a multicentric retrospective study that included patients receiving a diagnosis of MM during SLE. Ten patients were included (8 women and 2 men, median age at MM diagnosis: 40.4 years). SLE was diagnosed before MM in 9/10 patients (median time 8.2 years). When MM occurred, the SLEDAI score was ≥6 for 6/9 patients. Presenting symptoms consisted of sensory deficits (n = 10), neuropathic pain (n = 9), and/or motor deficits (n = 9), sometimes symmetrical, affecting the lower limbs (10/10) and occasionally the upper limbs (5/10). All patients presented with uni- or bilateral damage of the common fibular nerve, with less frequent involvement of the tibial nerve. Serum cryoglobulinemia was positive in 5/9 patients. Electrophysiological studies confirmed the non-symmetrical involvement of multiple nerve trunks in all patients. Neuromuscular biopsy (performed in five patients) showed histological signs of vasculitis in two patients and perivascular lymphocytic inflammatory infiltrates in two others. All patients were treated with glucocorticosteroids combined with cyclophosphamide (n = 6), rituximab (n = 3), or mycophénolate-mofétil (n = 1). The median follow-up was 5 years. Two patients relapsed during follow-up. All patients had motor and/or sensory sequelae upon follow-up. MM associated with SLE is frequently caused by a vasculitis mechanism. Patients improve with steroids and immunosuppressive drugs. Long-term outcomes include frequent clinical sequelae and possible relapses.

Entities:  

Keywords:  Mononeuritis multiplex; Rituximab; Systemic lupus erythematosus; Vasculitis

Mesh:

Substances:

Year:  2017        PMID: 28536920     DOI: 10.1007/s00415-017-8519-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort.

Authors:  Alan M Borowoy; Janet E Pope; Earl Silverman; Paul R Fortin; Christian Pineau; C Douglas Smith; Hector Arbillaga; Dafna Gladman; Murray Urowitz; Michel Zummer; Marie Hudson; Lori Tucker; Christine Peschken
Journal:  Semin Arthritis Rheum       Date:  2012-05-16       Impact factor: 5.532

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Clinical and electrophysiological characteristics of symmetric polyneuropathy in a cohort of systemic lupus erythematosus patients.

Authors:  R Jasmin; S Sockalingam; L P Ramanaidu; K J Goh
Journal:  Lupus       Date:  2014-09-24       Impact factor: 2.911

4.  Peripheral neuropathy in systemic lupus erythematosus.

Authors:  C Huynh; S L Ho; K Y Fong; R T Cheung; C C Mok; C S Lau
Journal:  J Clin Neurophysiol       Date:  1999-03       Impact factor: 2.177

5.  Peripheral neuropathy in patients with systemic lupus erythematosus.

Authors:  Brandusa Florica; Ellie Aghdassi; Jiandong Su; Dafna D Gladman; Murray B Urowitz; Paul R Fortin
Journal:  Semin Arthritis Rheum       Date:  2011-10       Impact factor: 5.532

6.  Mononeuritis multiplex, protein-losing gastroenteropathy, and choroidopathy seen together in a case of systemic lupus erythematosus.

Authors:  Yasuhiko Hirabayashi; Shinichiro Saito; Miki Watanabe Takeshita; Takao Kodera; Yasuhiko Munakata; Tomonori Ishii; Hiroshi Fujii; Masahiko Shimura; Takeshi Sasaki
Journal:  Mod Rheumatol       Date:  2003-09       Impact factor: 3.023

7.  Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus.

Authors:  Chi Chiu Mok; Chi Hung To; Anselm Mak
Journal:  Medicine (Baltimore)       Date:  2006-07       Impact factor: 1.889

Review 8.  Paediatric mononeuritis multiplex: a report of three cases and review of the literature.

Authors:  Monique M Ryan; Ann Tilton; Umberto De Girolami; Basil T Darras; H Royden Jones
Journal:  Neuromuscul Disord       Date:  2003-11       Impact factor: 4.296

9.  Mononeuritis multiplex complicating systemic lupus erythematosus.

Authors:  Arijit Bhowmik; Prabhabati Banerjee
Journal:  Indian Pediatr       Date:  2012-07       Impact factor: 1.411

Review 10.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03
View more
  4 in total

Review 1.  Neurological Complications in Patients with Systemic Lupus Erythematosus.

Authors:  Amir Shaban; Enrique C Leira
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 6.030

Review 2.  Neurological Disease in Lupus: Toward a Personalized Medicine Approach.

Authors:  Sarah McGlasson; Stewart Wiseman; Joanna Wardlaw; Neeraj Dhaun; David P J Hunt
Journal:  Front Immunol       Date:  2018-06-06       Impact factor: 8.786

3.  Bioinformatic Analysis of Neuroimmune Mechanism of Neuropathic Pain.

Authors:  Hao Yu; Yang Liu; Chao Li; Jianhao Wang; Bo Yu; Qiang Wu; Ziqian Xiang; Shiqing Feng
Journal:  Biomed Res Int       Date:  2020-08-28       Impact factor: 3.411

Review 4.  Immune Axonal Neuropathies Associated With Systemic Autoimmune Rheumatic Diseases.

Authors:  Delia Tulbă; Bogdan Ovidiu Popescu; Emilia Manole; Cristian Băicuș
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.